{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:57:10Z","timestamp":1790035030829,"version":"4.0.1"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["10.13039\/100009945"],"award-info":[{"award-number":["10.13039\/100009945"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the healthcare business of Merck KGaA, Darmstadt, Germany, and Pfizer"},{"name":"the Memorial Sloan Kettering Cancer Center Support Grant\/Core Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL141466, R01HL155990, R01HL156021, R01HL160688, R01HL170038"],"award-info":[{"award-number":["R01HL141466, R01HL155990, R01HL156021, R01HL160688, R01HL170038"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Clinical evidence to assess the utility of routine cardiac biomarker surveillance during immune checkpoint inhibitor treatment is limited. We examined cardiac biomarkers at baseline and during initial treatment in the JAVELIN Renal 101 phase 3 trial of avelumab plus axitinib vs sunitinib in patients with previously untreated advanced renal cell carcinoma (NCT02684006). At baseline, among available patients, levels of troponin T, troponin I, B-type natriuretic peptide (BNP), and N-terminal pro-BNP were high (per local assay) in 19.8%, 1.5%, 13.0%, and 32.8%, respectively. In addition, a notable proportion of patients developed high cardiac biomarker levels during treatment in both arms. We did not find an association between elevation in cardiac biomarkers and incidence of major adverse cardiac events, although assessment was limited by the small number of events. Overall, these findings suggest that a high proportion of patients with cancer may have elevated cardiac biomarkers at baseline. Therefore, any attempt at routine surveillance of cardiac biomarkers must include testing of the same biomarker at baseline (before initiating cancer treatment).<\/jats:p>","DOI":"10.1093\/oncolo\/oyag079","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:41:46Z","timestamp":1774615306000},"source":"Crossref","is-referenced-by-count":2,"title":["Cardiac biomarkers in patients with renal cell carcinoma treated with immune checkpoint inhibitors"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5960-6483","authenticated-orcid":false,"given":"Yen-Chou","family":"Chen","sequence":"first","affiliation":[{"name":"Section of Cardio-Oncology and Immunology, Division of Cardiology, and the Cardiovascular Research Institute, University of California , San Francisco, CA 94143,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandar A","family":"Aras","sequence":"additional","affiliation":[{"name":"Section of Cardio-Oncology and Immunology, Division of Cardiology, and the Cardiovascular Research Institute, University of California , San Francisco, CA 94143,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2212-080X","authenticated-orcid":false,"given":"Brian I","family":"Rini","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt-Ingram Cancer Center , Nashville, TN 37232,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K","family":"Choueiri","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA 02215,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cislo","sequence":"additional","affiliation":[{"name":"Pfizer , New York, NY 10001,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Motzer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10021,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5443-4312","authenticated-orcid":false,"given":"Javid","family":"Moslehi","sequence":"additional","affiliation":[{"name":"Section of Cardio-Oncology and Immunology, Division of Cardiology, and the Cardiovascular Research Institute, University of California , San Francisco, CA 94143,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"2026050622220061000_oyag079-B1","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026050622220061000_oyag079-B2","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1200\/JCO.21.01806","article-title":"Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell cancer: data from the phase III JAVELIN renal 101 trial","volume":"40","author":"Rini","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026050622220061000_oyag079-B3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"2026050622220061000_oyag079-B4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaccao.2021.01.004","article-title":"Myocarditis surveillance with high-sensitivity troponin I during cancer treatment with immune checkpoint inhibitors","volume":"3","author":"Waliany","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2026050622220061000_oyag079-B5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/CIRCULATIONAHA.123.062405","article-title":"Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis","volume":"148","author":"Lehmann","year":"2023","journal-title":"Circulation"},{"key":"2026050622220061000_oyag079-B6","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","article-title":"Fourth Universal Definition of Myocardial Infarction (2018)","volume":"138","author":"Thygesen","year":"2018","journal-title":"Circulation"},{"key":"2026050622220061000_oyag079-B7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ejhf.1494","article-title":"Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations","volume":"21","author":"Mueller","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026050622220061000_oyag079-B8","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2026050622220061000_oyag079-B9","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/eurheartj\/ehaf315","article-title":"Immune checkpoint inhibitor-associated myocarditis: a novel risk score","volume":"47","author":"Power","year":"2026","journal-title":"Eur Heart J"},{"key":"2026050622220061000_oyag079-B10","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1038\/s41591-023-02591-2","article-title":"Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis","volume":"29","author":"Fenioux","year":"2023","journal-title":"Nat Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag079\/67661195\/oyag079.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag079\/67661195\/oyag079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag079\/67661195\/oyag079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T02:22:08Z","timestamp":1778120528000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag079\/8560079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag079","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,3,30]]},"article-number":"oyag079"}}